Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 9, 2021

AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study

AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.

AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.

The clinical study, titled ‘A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects’, is being conducted by the Centre for Human Drug Research (CHDR) institute in the Netherlands.

The study intends to enrol a total of 40 healthy participants with eight each in four Ampligen treatment arms and a placebo arm.

Funded by AIM ImmunoTech, it is designed to evaluate the safety, tolerability, and biological activity of a repeated administration of intranasal Ampligen.

Participants will be given intranasal dosing every other day for a total of 13 days and seven doses.

According to a previous in vitro modelling at The Institute for Antiviral Research at Utah State University, Ampligen demonstrated to lower SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

AIM ImmunoTech CEO Thomas Equels said: “We greatly appreciate the tremendous efforts of the entire team at CHDR to help us initiate our Phase 1 study of Ampligen as a potential intranasal therapy.

“Our objective is to expedite the development of Ampligen as potential prophylaxis or treatment for Covid-19.

“Prior results of in vitro modelling were promising, and we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of Covid-19.”

Last month, AIM received approval from the required Ethics Committee in the Netherlands to initiate the Phase I clinical study of Ampligen as an intranasal therapy.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU